Med Pride Hydrocortisone Cream Recall Issued
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Dabur India Limited is recalling 4,944 tubes of Med Pride Hydrocortisone Cream 1% due to CGMP deviations observed during FDA inspection.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 1, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Dabur India Limited initiated a voluntary recall of Med Pride Hydrocortisone Cream 1% due to CGMP deviations and deficiencies observed during an FDA inspection.
Which Products Are Affected
Med Pride, HYDROCORTISONE CREAM 1%, Net Wt. 1 oz (28.3g) tubes, Manufactured for: Shield Line LLC, 59 Hook Road, Bayonne, NJ 07002 USA, Made in India, UPC 3 52410 30503 0. Affected lots: 001, 002, 013, 016, 031, 032, 033, 045, 046, 047 (within expiry). A total of 4,944 tubes were distributed US Nationwide. Recall number D-0640-2026.
What You Should Do
Consumers should refer to FDA guidance regarding the ongoing Class II recall.
Why This Matters
This Class II recall addresses manufacturing practice deviations that could pose temporary or reversible health consequences.
Source
FDA recall D-0640-2026, report date 20260624.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (854 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 1, 2026.
Frequently Asked Questions
Common questions about this FDA recall.